Immix Biopharma (NASDAQ:IMMX) Price Target Raised to $15.00 at Mizuho

Immix Biopharma (NASDAQ:IMMX) had its price target raised by Mizuho from $14.00 to $15.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other research analysts have also issued research reports about the company. Morgan Stanley initiated coverage on Immix Biopharma in a research report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Citizens Jmp reissued a “market outperform” rating and set a $23.00 price objective on shares of Immix Biopharma in a research note on Friday. Finally, HC Wainwright raised their target price on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Friday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immix Biopharma has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Immix Biopharma Stock Up 5.3%

NASDAQ:IMMX opened at $8.58 on Monday. The firm’s fifty day simple moving average is $7.85 and its 200 day simple moving average is $5.33. The stock has a market cap of $454.48 million, a P/E ratio of -9.64 and a beta of 0.25. Immix Biopharma has a twelve month low of $1.34 and a twelve month high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Wednesday, March 25th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, analysts expect that Immix Biopharma will post -0.87 EPS for the current fiscal year.

Institutional Trading of Immix Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP purchased a new position in shares of Immix Biopharma in the fourth quarter worth $30,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma during the fourth quarter valued at approximately $56,000. Balyasny Asset Management L.P. bought a new position in Immix Biopharma during the fourth quarter valued at approximately $67,000. Kera Capital Partners Inc. purchased a new stake in Immix Biopharma in the fourth quarter worth approximately $68,000. Finally, Squarepoint Ops LLC bought a new stake in Immix Biopharma in the 4th quarter worth approximately $112,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.